Opinions David Driscoll
Ipsen SAIPSEYTOP PICKFeb 15, 2019
Targetting oncology mostly. Small cap. Growing at a rapid rate. Debt to EBITDA is only 2x. Spending 13% of revenues on R&D, which is pretty hefty. (Analysts’ price target is $143.07)
David DriscollOwned
$35.10
Stock price when the opinion was issued
$48.52
As of Jul 09, 2026. Market Open.
0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
